The future of eye treatment could focus on vivo gene therapy, using recent studies as the basis for breakthrough treatments.
That is the opinion of Dr James M. Wilson, editor in chief of the journal Human Gene Therapy, who pointed to a recent study by Mao et al, which describes the delivery of a normal copy of the rhodopsin gene to mice with ocular disease caused by a mutated RHO gene and its subsequent ability to slow the rate of retinal degeneration.
According to Dr Wilson, the most dramatic clinical success of vivo gene therapy has been realised using AAV vectors when treating a rare and inherited form of congenital blindness.
He added: "Some level of functional improvement was realised in three independent trials. A number of scientists from around the world are progressing in vivo gene therapy into a number of other ocular disorders."
Meanwhile, new studies into the development of retinopathy of prematurity and how it can be stopped or slowed at Queen"s University, Belfast, have the potential to change the lives of thousands of children, researchers have claimed.
by Alexa Kaczka